Cargando…

Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma

PURPOSE: In recent years, docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy (CCRT) has been commonly applied for locally advanced nasopharyngeal carcinoma (LA-NPC). However, whether TPF+CCRT regimen is the best choice for LA-NPC remains uncle...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ruijuan, Lu, Yongkai, Zhang, Yuemei, He, Ruixin, Tang, Fengwen, Yuan, Wei, Li, Yi, Zhang, Xiaowei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542149/
https://www.ncbi.nlm.nih.gov/pubmed/34678878
http://dx.doi.org/10.1097/MD.0000000000027475
_version_ 1784589381091196928
author Chen, Ruijuan
Lu, Yongkai
Zhang, Yuemei
He, Ruixin
Tang, Fengwen
Yuan, Wei
Li, Yi
Zhang, Xiaowei
author_facet Chen, Ruijuan
Lu, Yongkai
Zhang, Yuemei
He, Ruixin
Tang, Fengwen
Yuan, Wei
Li, Yi
Zhang, Xiaowei
author_sort Chen, Ruijuan
collection PubMed
description PURPOSE: In recent years, docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy (CCRT) has been commonly applied for locally advanced nasopharyngeal carcinoma (LA-NPC). However, whether TPF+CCRT regimen is the best choice for LA-NPC remains unclear. This meta-analysis aims to elucidate and compare the efficacy and toxicity of TPF+CCRT versus CCRT alone for LA-NPC. METHODS: Two investigators independently and systematically searched relevant studies available on PubMed, Embase, Cochrane Library, and Web of Science published before January 7, 2021. Data were extracted from eligible studies for assessing their qualities, and calculating pooled hazard ratios (HR), odds ratio (OR) and 95% confidence intervals (CI) using Review Manager software 5.3 (RevMan 5.3). RESULTS: Five studies involving 759 LA-NPC patients were analyzed in the meta-analysis. Compared to CCRT alone, TPF-based IC plus CCRT significantly improved overall survival (OS) (HR = 0.53, 95% CI: 0.35–0.81, P = .003), progression-free survival (PFS) (HR = 0.63, 95% CI: 0.46–0.86, P = .004), distant metastasis-free survival (DMFS) (HR = 0.58, 95% CI: 0.39–0.86, P = .008), and locoregional failure-free survival (LRFFS) (HR 0.62, 95% CI: 0.43–0.90, P = .01). In addition, TPF-based IC plus CCRT mainly increased risks of grade 3/4 acute hematological toxicity and non-hematological toxicities like leukopenia (OR = 1.84, 95% CI: 0.42–8.03, P = .42), neutropenia (OR = 1.78, 95% CI: 0.23–13.82, P = .58), thrombocytopenia (OR = 1.76, 95% CI: 0.53–5.81, P = .35), febrile neutropenia (OR = 2.76, 95% CI: 0.07–101.89, P = .58), vomiting (OR = 18.94, 95% CI: 0.99–362.02, P = .05) and dry mouth (OR = 2.23, 95% CI: 0.22–22.57, P = .50), which were uncomplicated and manageable. CONCLUSIONS: TPF + CCRT is superb than CCRT alone for the management of LA-NPC. However, TPF+CCRT increases the incidences of grade 3/4 acute hematological toxicity and some non-hematological toxicities.
format Online
Article
Text
id pubmed-8542149
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-85421492021-10-25 Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma Chen, Ruijuan Lu, Yongkai Zhang, Yuemei He, Ruixin Tang, Fengwen Yuan, Wei Li, Yi Zhang, Xiaowei Medicine (Baltimore) 5700 PURPOSE: In recent years, docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy (CCRT) has been commonly applied for locally advanced nasopharyngeal carcinoma (LA-NPC). However, whether TPF+CCRT regimen is the best choice for LA-NPC remains unclear. This meta-analysis aims to elucidate and compare the efficacy and toxicity of TPF+CCRT versus CCRT alone for LA-NPC. METHODS: Two investigators independently and systematically searched relevant studies available on PubMed, Embase, Cochrane Library, and Web of Science published before January 7, 2021. Data were extracted from eligible studies for assessing their qualities, and calculating pooled hazard ratios (HR), odds ratio (OR) and 95% confidence intervals (CI) using Review Manager software 5.3 (RevMan 5.3). RESULTS: Five studies involving 759 LA-NPC patients were analyzed in the meta-analysis. Compared to CCRT alone, TPF-based IC plus CCRT significantly improved overall survival (OS) (HR = 0.53, 95% CI: 0.35–0.81, P = .003), progression-free survival (PFS) (HR = 0.63, 95% CI: 0.46–0.86, P = .004), distant metastasis-free survival (DMFS) (HR = 0.58, 95% CI: 0.39–0.86, P = .008), and locoregional failure-free survival (LRFFS) (HR 0.62, 95% CI: 0.43–0.90, P = .01). In addition, TPF-based IC plus CCRT mainly increased risks of grade 3/4 acute hematological toxicity and non-hematological toxicities like leukopenia (OR = 1.84, 95% CI: 0.42–8.03, P = .42), neutropenia (OR = 1.78, 95% CI: 0.23–13.82, P = .58), thrombocytopenia (OR = 1.76, 95% CI: 0.53–5.81, P = .35), febrile neutropenia (OR = 2.76, 95% CI: 0.07–101.89, P = .58), vomiting (OR = 18.94, 95% CI: 0.99–362.02, P = .05) and dry mouth (OR = 2.23, 95% CI: 0.22–22.57, P = .50), which were uncomplicated and manageable. CONCLUSIONS: TPF + CCRT is superb than CCRT alone for the management of LA-NPC. However, TPF+CCRT increases the incidences of grade 3/4 acute hematological toxicity and some non-hematological toxicities. Lippincott Williams & Wilkins 2021-10-22 /pmc/articles/PMC8542149/ /pubmed/34678878 http://dx.doi.org/10.1097/MD.0000000000027475 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/)
spellingShingle 5700
Chen, Ruijuan
Lu, Yongkai
Zhang, Yuemei
He, Ruixin
Tang, Fengwen
Yuan, Wei
Li, Yi
Zhang, Xiaowei
Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma
title Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma
title_full Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma
title_fullStr Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma
title_full_unstemmed Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma
title_short Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma
title_sort comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (tpf)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542149/
https://www.ncbi.nlm.nih.gov/pubmed/34678878
http://dx.doi.org/10.1097/MD.0000000000027475
work_keys_str_mv AT chenruijuan comparisonoftherapeuticefficacyandtoxicityofdocetaxelcisplatinandfluorouraciltpfbasedinductionchemotherapyplusconcurrentchemoradiotherapyandchemoradiotherapyaloneinlocallyadvancednasopharyngealcarcinoma
AT luyongkai comparisonoftherapeuticefficacyandtoxicityofdocetaxelcisplatinandfluorouraciltpfbasedinductionchemotherapyplusconcurrentchemoradiotherapyandchemoradiotherapyaloneinlocallyadvancednasopharyngealcarcinoma
AT zhangyuemei comparisonoftherapeuticefficacyandtoxicityofdocetaxelcisplatinandfluorouraciltpfbasedinductionchemotherapyplusconcurrentchemoradiotherapyandchemoradiotherapyaloneinlocallyadvancednasopharyngealcarcinoma
AT heruixin comparisonoftherapeuticefficacyandtoxicityofdocetaxelcisplatinandfluorouraciltpfbasedinductionchemotherapyplusconcurrentchemoradiotherapyandchemoradiotherapyaloneinlocallyadvancednasopharyngealcarcinoma
AT tangfengwen comparisonoftherapeuticefficacyandtoxicityofdocetaxelcisplatinandfluorouraciltpfbasedinductionchemotherapyplusconcurrentchemoradiotherapyandchemoradiotherapyaloneinlocallyadvancednasopharyngealcarcinoma
AT yuanwei comparisonoftherapeuticefficacyandtoxicityofdocetaxelcisplatinandfluorouraciltpfbasedinductionchemotherapyplusconcurrentchemoradiotherapyandchemoradiotherapyaloneinlocallyadvancednasopharyngealcarcinoma
AT liyi comparisonoftherapeuticefficacyandtoxicityofdocetaxelcisplatinandfluorouraciltpfbasedinductionchemotherapyplusconcurrentchemoradiotherapyandchemoradiotherapyaloneinlocallyadvancednasopharyngealcarcinoma
AT zhangxiaowei comparisonoftherapeuticefficacyandtoxicityofdocetaxelcisplatinandfluorouraciltpfbasedinductionchemotherapyplusconcurrentchemoradiotherapyandchemoradiotherapyaloneinlocallyadvancednasopharyngealcarcinoma